More frequently reported side effects include: fatigue.
See below for a comprehensive list of adverse effects.
If any of the following symptoms of overdose occur while taking bisoprolol, get emergency help immediately:
The more commonly reported side effects observed with this drug are bradycardia, dizziness, and hypotension.
Bradycardia occurred as a dose-related event.
Cardiac failure occurred in 18.
4% of patients (n=1328) compared with 22.
8% of placebo-treated patients (n=1321).
Very common (10% or more): Bradycardia (up to 15.
2%)Common (1% to 10%): Chest pain, heart failure aggravation, hypotension, cold extremities, peripheral edema, ischemia, conduction disorder, left cardiac failure, palpitation, vein disorderUncommon (0.
1% to 1%): Atrioventricular (AV) disturbances, orthostatic hypotensionFrequency not reported: Other rhythm disturbances, claudication
Very common (10% or more): Dizziness (up to 13.
3%)Common (1% to 10%): Headache, extremity numbness, cerebrovascular disorder, syncope, hypoesthesiaFrequency not reported: Vertigo, paresthesia, hypoesthesia, hyperesthesia, somnolence, decreased concentration/memory, tremor, taste abnormalitiesPostmarketing reports: Unsteadiness
Very common (10% or more): Dyspnea (up to 13.
8%)Common (1% to 10%): Pneumonia, bronchitis, coughing, exertional dyspnea, upper respiratory tract infection, respiratory distress, stridor, respiratory tract edema, respiratory tract hemorrhage, sinusitisUncommon (0.
1% to 1%): Bronchospasm Rare (0.
01% to 0.
1%): Allergic rhinitis
Sinusitis occurred as a dose-related event.
Very common: Antinuclear antibody (ANA) conversions (up to 15%)Common (1% to 10%): Viral infection
Common (1% to 10%): PruritusUncommon (0.
1% to 1%): SweatingRare (0.
01% to 0.
1%): Itching, flushing, rashVery rare (less than 0.
01%): Alopecia, psoriasis-like rash, psoriasis exacerbationFrequency not reported: Acne, eczema, skin irritation, cutaneous vasculitisPostmarketing reports: Dermatitis, exfoliative dermatitis
Diarrhea occurred as a dose-related event.
Common (1% to 10%): Nausea, vomiting, diarrhea, constipation, dyspepsia, epigastric pain (not food related), abdominal pain, gastritis, dry mouthFrequency not reported: Gastric pain, peptic ulcer
Common (1% to 10%): Purine metabolism disorder, carbohydrate metabolism disturbed, weight changes, cholesterol changes, potassium levels altered, blood lipid changesRare (0.
01% to 0.
1%): Increased triglyceridesFrequency not reported: GoutPostmarketing reports: Increased uric acid and glucose
Uric acid, serum potassium, glucose, and phosphorus increases associated with use of this drug were not of clinical importance and rarely resulted in discontinuation.
Common (1% to 10%): Limb pain, myalgia, arthropathy, arthralgiaUncommon (0.
1% to 1%): Muscular weakness, cramps Frequency not reported: Back pain, neck pain, twitching
Common (1% to 10%): Asthenia, fatigue, body pain, fever, malaiseRare (0.
01% to 0.
1%): Hearing disordersFrequency not reported: Earache, tinnitus
Fatigue and asthenia occurred as dose-related events.
Common (1% to 10%): Insomnia, anxietyUncommon (0.
1% to 1%): Sleep disorders, depressionRare (0.
01% to 0.
1%): Nightmares, hallucinations Frequency not reported: Restlessness
Common (1% to 10%): Urinary tract infectionRare (0.
01% to 0.
1%): Potency disorders Frequency not reported: Decreased libido, Peyronie's disease, polyuria
Common (1% to 10%): HepatomegalyRare (0.
01% to 0.
1%): Increased liver enzymes (ALT, AST), hepatitis
Transaminase elevations of 1 to 2 times the upper limit of normal were reported in 6.
2% of patients, with a multiple occurrence rate of 1.
9%.
Generally, this increase was the result of underlying disorders or resolved with continued use of this drug.
Rare (0.
01% to 0.
1%): Hypersensitivity Postmarketing reports: Angioedema
Of the 15% of patients who developed positive ANA status, one-third of patients converted back to a negative titer with continued use.
Rare (0.
01% to 0.
1%): Reduced tear flow Very rare (less than 0.
01%): ConjunctivitisFrequency not reported: Visual disturbances, ocular pain, ocular pressure
Creatinine and BUN were associated with slightly increased levels, but these effects were generally not of clinical importance and rarely resulted in discontinuation.
Frequency not reported: Cystitis, renal colicPostmarketing reports: Increased creatinine and BUN
During treatment with this drug, decreased levels of WBCs and platelets were not of clinical importance and rarely resulted in discontinuation.
Postmarketing reports: Purpura, decreases in WBC and platelets
Body aches or pain
chest pain
chills
cough
difficult or labored breathing
ear congestion
fever
headache
loss of voice
nasal congestion
pain or tenderness around eyes and cheekbones
shortness of breath or troubled breathing
sneezing
sore throat
stuffy or runny nose
tightness in chest
unusual tiredness or weakness
wheezing
Chest discomfort
lightheadedness, dizziness, or fainting
slow or irregular heartbeat
Anxiety
blurred vision
cold sweats
coma
confusion
cool, pale skin
decreased urine output
depression
dilated neck veins
dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
extreme fatigue
fast heartbeat
increased hunger
irregular breathing
nausea
nervousness
nightmares
noisy breathing
seizures
shakiness
slurred speech
sweating
swelling of face, fingers, feet, or lower legs
weight gain
Abnormal or decreased touch sensation
diarrhea
difficulty in moving
lack or loss of strength
muscle pain or stiffness
pain in joints
sleeplessness
trouble sleeping
unable to sleep
vomiting